In Vitro, In Vivo, and Parallel Phase I Evidence Support the Safety and Activity of Duvelisib, a PI3K-δ,γ Inhibitor, in Combination with Romidepsin or Bortezomib in Relapsed/Refractory T-Cell Lymphoma
Year: 2017
Type: conference-abstract
Source: Blood
Authors: Alison J. Moskowitz, Raphael Koch, Neha Mehta-Shah, Patricia Myskowski, Meenal Kheterpal, Ahmet Dogan, Theresa Davey, Natasha Galasso, Marzouk Evan, Monica Shah, Nivetha Ganesan, Lakeisha Lubin, Youn H. Kim, Michael Khodadoust, Timothy Almazan, Julia Dai, Eric D. Jacobsen, David M. Weinstock, Steven M. Horwitz
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2965664826